Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Phathom Pharmaceuticals Inc
(NQ:
PHAT
)
10.30
-0.10 (-0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Phathom Pharmaceuticals Inc
< Previous
1
2
3
Next >
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 23, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
May 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 10, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
May 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
April 16, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Near the Top of Equities by Percentage Gain on 4/13
April 13, 2023
Via
Investor Brand Network
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 12, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
April 09, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
April 04, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
March 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
March 06, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
March 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
March 01, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
February 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
February 19, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Investor Alert: Investigation over Potential Wrongdoing
February 17, 2023
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investigation on behalf of investors in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) was announced over potential breaches of fiduciary duties by...
Via
SBWire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 14, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Phathom Pharmaceuticals Provides Regulatory Updates
February 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
February 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
January 18, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
January 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 08, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 03, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
NASDAQ:PHAT Shareholder Alert: Investigation over Possible Securities Laws Violations by Phathom Pharmaceuticals, Inc.
November 15, 2022
San Diego, CA -- (SBWIRE) -- 11/15/2022 -- Phathom Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 03, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
November 01, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
October 24, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.